Patent · US Active

SHMT inhibitors

US10077273B2 · kind B2 · utility

6Cited by
2References
15Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 14, 2017
Grant dateSep 18, 2018
Priority date
Expiry dateSep 14, 2037

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K45/06
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The disclosure provides compounds of Formulae (I)-(IX). The disclosed compounds are capable of inhibiting a mammalian SHMT. Compounds of the disclosure have numerous uses, such as for treatment of cancer or autoimmune disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.